D-0958-2017 Class I Terminated

Recalled by AstraZeneca Pharmaceuticals, LP — Newark, DE

Recall Details

Product Type
Drugs
Report Date
July 19, 2017
Initiation Date
May 25, 2017
Termination Date
April 24, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
40,368 bottles

Product Description

BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.

Reason for Recall

Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

Distribution Pattern

Nationwide in the USA and Puerto Rico to physician offices.

Code Information

Lot # JB5047, Exp 10/19